These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38511952)

  • 1. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
    Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
    Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of immunity against Yellow Fever virus infections in northeastern Nigeria using three serological assays.
    Baba MM; Yahaya KM; Ezra EM; Adamu M; Kulloma BM; Ikusemoran M; Momoh JP; Oderinde BS
    J Med Virol; 2021 Aug; 93(8):4856-4864. PubMed ID: 33783842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.
    Kareko BW; Booty BL; Nix CD; Lyski ZL; Slifka MK; Amanna IJ; Messer WB
    J Infect Dis; 2020 Jun; 221(12):2018-2025. PubMed ID: 31545367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
    Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sero-prevalence of yellow fever and related Flavi viruses in Ethiopia: a public health perspective.
    Mengesha Tsegaye M; Beyene B; Ayele W; Abebe A; Tareke I; Sall A; Yactayo S; Shibeshi ME; Staples E; Belay D; Lilay A; Alemu A; Alemu E; Kume A; H/Mariam A; Ronveaux O; Tefera M; Kassa W; Bekele Weyessa A; Jima D; Kebede A; Tayachew A
    BMC Public Health; 2018 Aug; 18(1):1011. PubMed ID: 30107830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for multiple sylvatic transmission cycles during the 2016-2017 yellow fever virus outbreak, Brazil.
    Moreira-Soto A; Torres MC; Lima de Mendonça MC; Mares-Guia MA; Dos Santos Rodrigues CD; Fabri AA; Dos Santos CC; Machado Araújo ES; Fischer C; Ribeiro Nogueira RM; Drosten C; Sequeira PC; Drexler JF; Bispo de Filippis AM
    Clin Microbiol Infect; 2018 Sep; 24(9):1019.e1-1019.e4. PubMed ID: 29427798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
    da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
    Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
    Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
    Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
    J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients.
    Avelino-Silva VI; Miyaji KT; Hunt PW; Huang Y; Simoes M; Lima SB; Freire MS; Caiaffa-Filho HH; Hong MA; Costa DA; Dias JZ; Cerqueira NB; Nishiya AS; Sabino EC; Sartori AM; Kallas EG
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005219. PubMed ID: 27941965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.
    Campi-Azevedo AC; de Araújo-Porto LP; Luiza-Silva M; Batista MA; Martins MA; Sathler-Avelar R; da Silveira-Lemos D; Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Farias RH; da Silva Freire M; Galler R; Homma A; Ribeiro JG; Lemos JA; Auxiliadora-Martins M; Caldas IR; Elói-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
    PLoS One; 2012; 7(12):e49828. PubMed ID: 23251351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
    J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of immunity in recipients of two doses of 17DD yellow fever vaccine.
    Collaborative group for studies on yellow fever vaccines
    Vaccine; 2019 Aug; 37(35):5129-5135. PubMed ID: 31171393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
    Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
    J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of YF-neutralizing antibodies in vulnerable populations of Brazil: A warning for epidemiological surveillance and the potential risks for future outbreaks.
    Stoffella-Dutra AG; Silva de Oliveira J; Barbosa Costa G; Geessien Kroon E; Santos Abrahão J; Desiree LaBeaud A; Paiva Drumond B; Bretas de Oliveira D; de Souza Trindade G
    Vaccine; 2020 Sep; 38(42):6592-6599. PubMed ID: 32788140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of post-vaccination humoral immunity against yellow fever in children.
    de Noronha TG; de Lourdes de Sousa Maia M; Geraldo Leite Ribeiro J; Campos Lemos JA; Maria Barbosa de Lima S; Martins-Filho OA; Campi-Azevedo AC; da Silva Freire M; de Menezes Martins R; Bastos Camacho LA;
    Vaccine; 2019 Nov; 37(48):7147-7154. PubMed ID: 31590934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
    Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
    J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
    Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.